GT200500028A - Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos. - Google Patents

Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.

Info

Publication number
GT200500028A
GT200500028A GT200500028A GT200500028A GT200500028A GT 200500028 A GT200500028 A GT 200500028A GT 200500028 A GT200500028 A GT 200500028A GT 200500028 A GT200500028 A GT 200500028A GT 200500028 A GT200500028 A GT 200500028A
Authority
GT
Guatemala
Prior art keywords
oxadiazolones
pharmaceutical products
procedures
preparation
useful
Prior art date
Application number
GT200500028A
Other languages
English (en)
Inventor
Jochen Goerlitzer
Stefanie Keil
Maike Glien
Wolfgang Wendler
Daniel G Mcgarry
Jean Merrill
Karen Chandross
Patrick Bernadelli
Baptiste Ronan
Corinne Terrier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500028A publication Critical patent/GT200500028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A OXADIAZOLONAS DE FORMULA I ASI COMO A SUS SALES FISIOLOGICAMENTE ACEPTABLES, A SU PROCESO DE PREPARACION Y A SU USO COMO PRODUCTOS FARMACEUTICOS, ESTAS OXIDIAZOLONAS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE DESORDENES EN EL CUAL LA RESISTENCIA A LA INSULINA ES IMPORTANTE, TAMBIEN ES UTIL PARA EL TRATAMIENTO DE DESORDENES NEURODEGENERATIVOS ASI COMO ENFERMEDADES NEUROLOGICAS QUE CON LLEVAN PROCESOS NEUROINFLAMATORIOS O NEUROPATIAS PERIFERICAS.
GT200500028A 2004-04-01 2005-02-17 Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos. GT200500028A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (en) 2004-04-01 2004-04-01 Oxadiazolones, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
GT200500028A true GT200500028A (es) 2006-06-09

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500028A GT200500028A (es) 2004-04-01 2005-02-17 Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.

Country Status (38)

Country Link
US (3) US20070179191A1 (es)
EP (3) EP1586573B1 (es)
JP (1) JP2007530612A (es)
KR (1) KR20060135857A (es)
CN (1) CN100582104C (es)
AR (1) AR050576A1 (es)
AT (1) ATE435225T1 (es)
AU (1) AU2005231916A1 (es)
BR (1) BRPI0509517A (es)
CA (1) CA2561627A1 (es)
CR (1) CR8572A (es)
CY (1) CY1109370T1 (es)
DE (2) DE602004004631D1 (es)
DK (1) DK1740583T3 (es)
DO (1) DOP2005000051A (es)
EC (1) ECSP066892A (es)
ES (1) ES2329484T3 (es)
GT (1) GT200500028A (es)
HK (1) HK1100408A1 (es)
HR (1) HRP20090493T1 (es)
IL (1) IL178056A0 (es)
MA (1) MA28495B1 (es)
MY (1) MY142431A (es)
NO (1) NO20064981L (es)
PA (1) PA8628701A1 (es)
PE (1) PE20060323A1 (es)
PL (1) PL1740583T3 (es)
PT (1) PT1740583E (es)
RS (1) RS51186B (es)
RU (1) RU2374243C2 (es)
SI (1) SI1740583T1 (es)
SV (1) SV2006002071A (es)
TN (1) TNSN06317A1 (es)
TW (1) TW200602342A (es)
UA (1) UA84203C2 (es)
UY (1) UY28837A1 (es)
WO (1) WO2005097786A1 (es)
ZA (1) ZA200606870B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
BRPI0616477A2 (pt) 2005-09-29 2011-06-21 Sanofi Aventis derivados de 2-amintiazóis e 2-amino-oxazóis, processos para a sua preparação e seus usos
BRPI0616465A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
AU2007292874B2 (en) 2006-09-08 2013-11-21 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
EP2288607B1 (en) * 2008-06-09 2014-09-24 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2288605B1 (en) * 2008-06-09 2014-06-25 Sanofi Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8946212B2 (en) 2008-06-09 2015-02-03 Sanofi-Aventis Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
ES2567455T3 (es) 2008-10-10 2016-04-22 Dara Biosciences, Inc. Nanoemulsiones que comprenden derivados de espicamicina para su uso en el tratamiento del dolor
CN106243100B (zh) 2008-10-10 2019-04-09 Vm生物医药公司 治疗酒精使用障碍，疼痛和其他疾病的药物组合与方法
ES2439801T3 (es) * 2009-08-05 2014-01-24 Daiichi Sankyo Company, Limited Derivado de sulfona
RU2536409C2 (ru) * 2009-08-05 2014-12-20 Дайити Санкио Компани, Лимитед Амидное производное
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) * 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9707003A (pt) 1996-01-17 1999-07-20 Novo Nordisk As Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
ES2287016T3 (es) 1999-04-28 2007-12-16 Sanofi-Aventis Deutschland Gmbh Derivados de diaril-acido como ligandos del receptor ppar.
SK15522001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
JP2003506365A (ja) 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン：セロトニンアゴニスト
PL353367A1 (en) 1999-09-01 2003-11-17 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
ES2215769T3 (es) 1999-12-03 2004-10-16 Astrazeneca Ab Forma cristalina de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico.
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
KR20080067009A (ko) 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
EA004244B1 (ru) 2000-04-25 2004-02-26 Киорин Фармасьютикал Ко., Лтд. Новый стабильный кристалл производного тиазолидиндиона и способ его получения
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
SK17252002A3 (sk) 2000-06-09 2003-05-02 Aventis Pharma Deutschland Gmbh Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
ATE349425T1 (de) 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
WO2002067912A2 (en) 2001-02-22 2002-09-06 Smithkline Beecham Corporation Method for treating ppar gamma mediated diseases or conditions
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
UA76773C2 (uk) 2001-08-31 2006-09-15 Санофі-Авентіс Дойчланд Гмбх Діарилциклоалкільні похідні, спосіб їх одержання і їх застосування як ppar-активаторів
AU2002347985A1 (en) * 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1615900A1 (en) 2003-04-01 2006-01-18 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
WO2004094393A1 (en) 2003-04-01 2004-11-04 Eli Lilly And Company Phospholipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
BRPI0616465A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica

Also Published As

Publication number Publication date
AU2005231916A1 (en) 2005-10-20
PE20060323A1 (es) 2006-03-31
ECSP066892A (es) 2006-11-24
ATE435225T1 (de) 2009-07-15
UY28837A1 (es) 2005-10-31
KR20060135857A (ko) 2006-12-29
DOP2005000051A (es) 2005-12-15
US20080255212A1 (en) 2008-10-16
EP2083006A1 (en) 2009-07-29
UA84203C2 (en) 2008-09-25
HRP20090493T1 (en) 2009-10-31
AR050576A1 (es) 2006-11-08
IL178056A0 (en) 2006-12-31
PT1740583E (pt) 2009-09-16
EP1740583A1 (en) 2007-01-10
HK1100408A1 (en) 2007-09-21
JP2007530612A (ja) 2007-11-01
EP1586573B1 (en) 2007-02-07
CN1938300A (zh) 2007-03-28
US20070179191A1 (en) 2007-08-02
MY142431A (en) 2010-11-30
CN100582104C (zh) 2010-01-20
US7709509B2 (en) 2010-05-04
CR8572A (es) 2007-12-04
ES2329484T3 (es) 2009-11-26
BRPI0509517A (pt) 2007-09-11
DE602005015204D1 (de) 2009-08-13
TNSN06317A1 (en) 2007-12-03
PL1740583T3 (pl) 2009-12-31
EP1586573A1 (en) 2005-10-19
SV2006002071A (es) 2006-01-30
WO2005097786A1 (en) 2005-10-20
MA28495B1 (fr) 2007-03-01
RS51186B (sr) 2010-10-31
TW200602342A (en) 2006-01-16
DK1740583T3 (da) 2009-10-19
EP1740583B1 (en) 2009-07-01
RU2374243C2 (ru) 2009-11-27
RU2006138498A (ru) 2008-05-10
SI1740583T1 (sl) 2009-12-31
PA8628701A1 (es) 2006-11-25
US20080262052A1 (en) 2008-10-23
ZA200606870B (en) 2008-04-30
NO20064981L (no) 2006-12-28
CY1109370T1 (el) 2014-07-02
CA2561627A1 (en) 2005-10-20
DE602004004631D1 (de) 2007-03-22

Similar Documents

Publication Publication Date Title
GT200500028A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.
EA201200002A1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
CY1118902T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
CR20110509A (es) Composicion farmaceutica
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
UY30282A1 (es) Compuestos quimicos
UY31803A (es) Compuesto cristalino
UY29161A1 (es) Nuevos heterociclos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
GT200500070A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
NI201600160A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
NI201600161A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
GB2473579A (en) Stat3 and TYK2 as drug targets for neurodegenerative diseases
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6